KMT Stock Recent News

Kennametal (KMT) reported earnings 30 days ago. What's next for the stock?

Leading manufacturer announces series of machining demonstrations led by the industry's best PITTSBURGH , Aug. 27, 2024 /PRNewswire/ -- Kennametal Inc. (NYSE: KMT), has released its daily schedule of live machining demos for the weeklong "Metal Mania" exhibition at the International Manufacturing Technology Show (IMTS) in Chicago at McCormick Place, September 9-14, 2024. Attendees can browse tooling solutions from various Kennametal product brands, including Kennametal®, WIDIA™ and Hanita™ with the opportunity to watch innovations at work in live demos.

PITTSBURGH , Aug. 26, 2024 /PRNewswire/ -- Kennametal Inc. (NYSE: KMT) announced today that they will attend the Morgan Stanley 12th Annual Laguna Conference. Details of the conference are as follows: When: Thursday, September 12, 2024 Attendees:  Patrick Watson, Vice President and Chief Financial Officer Michael Pici, Vice President, Investor Relations Kelly Lynch, Vice President Finance, Metal Cutting Segment About Kennametal With over 85 years as an industrial technology leader, Kennametal Inc. delivers productivity to customers through materials science, tooling and wear-resistant solutions.

Kennametal (KMT) is poised to gain from strength across the aerospace & defense end markets. The company's measures to reward its shareholders are encouraging.

Machining center to come complete with exclusive Kennametal tooling PITTSBURGH , Aug. 13, 2024 /PRNewswire/ -- Kennametal Inc. (NYSE: KMT), an industrial technology leader, announced today that it will be giving attendees at the International Manufacturing Technology Show (IMTS), at McCormick Place in Chicago, September 9-14, 2024, the opportunity to take home a variety of prizes, including a CNC machine. The SVM 4100 Vertical Machining Center is the largest of the Kennametal giveaways at its Metal Mania booth located in the West Building, level 3, booth number 432324.

– Pivotal AUGMENT-101 trial met its primary endpoint at interim analysis of patients with KMT2Ar AML and ALL (p-value = 0.0036) – – NDA filing for revumenib in R/R KMT2Ar acute leukemia is being reviewed under RTOR; PDUFA action date of December 26, 2024 – WALTHAM, Mass. , Aug. 12, 2024 /PRNewswire/ -- Syndax Pharmaceuticals (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that data from the pivotal Phase 2 portion of the AUGMENT-101 trial of revumenib, a first-in-class menin inhibitor, in adult and pediatric patients with relapsed/refractory (R/R) KMT2A-rearranged (KMT2Ar) acute myeloid leukemia (AML) and acute lymphoid leukemia (ALL) have been published in the Journal of Clinical Oncology.

Kennametal's (KMT) fiscal fourth-quarter 2024 revenues decrease 1% due to the lackluster performance of the Metal Cutting segment.

Kennametal Inc. (NYSE:KMT ) Q4 2024 Earnings Conference Call August 7, 2024 9:30 AM ET Company Participants Michael Pici - Vice President of Investor Relations Sanjay Chowbey - President and Chief Executive Officer Pat Watson - Vice President and Chief Financial Officer Franklin Cardenas - Vice President and President of Infrastructure Conference Call Participants Grace Song - Morgan Stanley Joseph Ritchie - Goldman Sachs Julian Mitchell - Barclays Tami Zakaria - JPMorgan Steven Fisher - UBS Steve Barger - KeyBanc Capital Markets Michael Feniger - Bank of America Operator Good morning. I would like to welcome everyone to Kennametal Fourth Quarter and Fiscal 2024 Earnings Conference Call.

While the top- and bottom-line numbers for Kennametal (KMT) give a sense of how the business performed in the quarter ended June 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Kennametal (KMT) came out with quarterly earnings of $0.49 per share, beating the Zacks Consensus Estimate of $0.44 per share. This compares to earnings of $0.51 per share a year ago.